Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Microphthalmia, Isolated, with Coloboma 5 1Medulloblastoma 1Liposarcoma 1

Interventions

Vincristine 13Temozolomide 12Cyclophosphamide 11Irinotecan 8Magnetic Resonance Spectroscopy 7X-Rays 6Vinorelbine 6Specimen Handling 6Phantoms, Imaging 6Dactinomycin 6Biopsy 5fludarabine 4Radiotherapy 4Radiation 4Nuclear Medicine Department, Hospital 4Filgrastim 4Etoposide 4pegfilgrastim 3irinotecan sucrosofate 3Sirolimus 3Proton Therapy 3Melphalan 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdomyosarcoma × silmitasertib × 1 year × Clear all
NCT06541262 2026-04-09

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
104 enrolled
CNSSarcoma

Liposarcoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡